Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company is committed to providing affordable and innovative medicines. Dr. Reddy's reported annual revenue of USD 2.83 billion for the fiscal year 2022, an 8.94% increase from the previous year.

Dr. Reddy's offers a wide portfolio of products and services including active pharmaceutical ingredients (APIs), generic medicines, branded generics, biosimilars, and over-the-counter (OTC) products. The company's major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's has a significant presence in key markets such as the US, India, Russia, and Europe. The company operates 21 manufacturing facilities across 66 countries.

• Generic Medicines: Dr. Reddy's manufactures and markets a broad range of generic prescription drugs globally.

• APIs: The company produces bulk drugs and active pharmaceutical ingredients.

• Biosimilars: Dr. Reddy's develops biosimilar versions of biologic drugs for immunology and oncology.

• OTC Products: The company offers various over-the-counter consumer health products.

• Contract Research and Manufacturing: Through its subsidiary Aurigene, Dr. Reddy's provides drug discovery and development services.

Dr. Reddy's continues to expand through acquisitions and partnerships. In February 2023, the company announced an agreement to acquire the US generic prescription product portfolio of Mayne Pharma Group for approximately USD 90 million. Dr. Reddy's is also exploring opportunities in emerging areas like digital therapeutics. The company aims to reach 1.5 billion patients by 2030 and become one of the top five pharmaceutical companies in India through organic growth and strategic acquisitions.